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Abstract
Background: Variation in genes implicated in monoamine neurotransmission may interact with environmental factors to 
inluence antidepressant response. We aimed to determine how a range of single nucleotide polymorphisms in monoaminergic 
genes inluence this response to treatment and how they interact with childhood trauma and recent life stress in a Chinese 
sample. An initial study of monoaminergic coding region single nucleotide polymorphisms identiied signiicant associations 
of TPH2 and HTR1B single nucleotide polymorphisms with treatment response that showed interactions with childhood and 
recent life stress, respectively (Xu et al., 2012).
Methods: A total of 47 further single nucleotide polymorphisms in 17 candidate monoaminergic genes were genotyped in 
281 Chinese Han patients with major depressive disorder. Response to 6 weeks’ antidepressant treatment was determined 
by change in the 17-item Hamilton Depression Rating Scale score, and previous stressful events were evaluated by the Life 
Events Scale and Childhood Trauma Questionnaire-Short Form.
Results: Three TPH2 single nucleotide polymorphisms (rs11178998, rs7963717, and rs2171363) were signiicantly associated 
with antidepressant response in this Chinese sample, as was a haplotype in TPH2 (rs2171363 and rs1487278). One of these, 
rs2171363, showed a signiicant interaction with childhood adversity in its association with antidepressant response.
Conclusions: These indings provide further evidence that variation in TPH2 is associated with antidepressant response and 
may also interact with childhood trauma to inluence outcome of antidepressant treatment.
Keywords: depression, antidepressive agents, stress, TPH2, polymorphism, single nucleotide
Introduction
Major depressive disorder (MDD) is a major economic and social 
burden owing to its high prevalence rate and disabling symptoms 
(Kessler et al., 2005). Although the newer antidepressant drugs 
are generally well tolerated and relatively effective, less than 
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one-half of patients achieve remission with the irst prescribed 
antidepressant (Rush et  al., 2006). Partial remission results in 
continued suffering and higher costs (Tranter et al., 2002).
There have been many attempts to identify variables that 
could predict antidepressant response, with a variety of predic-
tors proposed that include clinical, psychosocial, psychophysi-
ological, neuropsychological, neuroimaging, and genetic factors 
(Bondy and Zill, 2004; Lohoff and Ferraro, 2010). While genetic 
polymorphisms may contribute 50% or more to antidepressant 
response, a more effective strategy should consider interactions 
between the various genetic factors (gene × gene) as well as their 
interaction with clinical and other environmental modulators 
(gene × environment) (Fabbri et al., 2014). In the main, genetic 
research focuses on genetic polymorphisms of target pro-
teins that relate to mechanisms of antidepressant drug action 
(Serretti et  al., 2005). As the monoaminergic theory remains 
the theoretical basis for the effect of most current antidepres-
sant drugs, a number of genes coding for metabolic enzymes, 
transporters, and receptors in monoamine systems have been 
studied and reported to affect antidepressant drug response 
(reviewed by Schosser and Kasper, 2009; Fabbri et al., 2014). As 
the serotonin transporter and the 5-HT1A receptor are strongly 
implicated in antidepressant action, their genetic variability has 
been well studied in this respect (Illi et al., 2009). Investigations 
into an insertion–deletion (L/S)polymorphism(5-HTTLPR)associ-
ated with antidepressant response found that L-allele carriers 
have a faster and better response to antidepressants, if they 
are Caucasians, but allele frequencies and results of pharmaco-
genetic studies vary between different ethnic groups (Karlović 
et al., 2013). Other genes involved in serotonin and noradrena-
line neurotransmission, including 5-HT6, 5-HT1A and 5-HT2A 
receptors, monoamine oxidase A, the noradrenaline transporter 
SLC6A2, and tryptophan hydroxylases (TPH1 and 2) among oth-
ers also provide good candidates for pharmacogenetic study 
(Schosseret al., 2009; Kishi et al., 2010; Lin et al., 2014). The single 
nucleotide polymorphism (SNP) rs6295 of 5-HT1A receptor has 
been widely studied, because the G allele was associated with an 
upregulation of the receptor (Albert et al., 2004). TPH2 is the rate-
limiting biosynthetic enzyme for serotonin that is preferentially 
expressed in the brain and has been implicated in the pathogen-
esis and treatment of major depressive disorder (Xu et al., 2012; 
Tsai et al., 2009). Several SNPs in this gene have been associated 
with affective disorders and their treatment response. Cichon 
et  al. (2008) found that the minor alleles of SNPs rs11178997 
(T-473A) and rs11178998 (A90G) in the 5’ region were signii-
cantly overrepresented in bipolar affective disorder patients 
when compared with controls. In a recent meta-analyses, it was 
found that rs4760820 and rs11178998 demonstrated a strong 
genetic association with bipolar disorder (Gao et al., 2016). The 
promoter polymorphism rs4570625 (T-703G) of TPH2 has been 
found associated with paranoid schizophrenia in Han Chinese 
(Xu et al., 2014).Tsai et al (2009) reported that the proportion of 
intron 5 SNP rs2171363 heterozygotes had an increased chance 
of responding to an 8-week antidepressant treatment as com-
pared with rs2171363 homozygotes (CC or TT).
Identifying environmental factors that may interact with 
different genetic pathways in determining antidepressant efi-
cacy would be a valuable step towards personalized medicine 
in the treatment of depression. Environmental factors such as 
childhood maltreatment and stressful life events certainly show 
independent effects on antidepressant response (Nanni et  al., 
2012), and there are several reports of signiicant interactions 
with genetic polymorphisms in these effects (Uher, 2014). Thus, 
Mandelli et al. (2009) reported that stressors modulate the effects 
of a common functional polymorphism (5-HTTLPR) of the sero-
tonin transporter gene (SLC6A4) on outcome of pharmacological 
treatment of depression. It was also found that variants in BDNF 
and ST8SIA may delay the early response to antidepressants 
in subjects not exposed to stressors at the illness onset, with a 
remarkable gene-environment interaction (Mandelli et al., 2014). 
Keers et al. (2011) also reported variation in the 5-HTTLPR and 
STin4 polymorphisms of SLC6A4 interacted with stressful life 
events to modify antidepressant effects. Our own studies identi-
ied that the HTR1B SNP rs6298 demonstrated interaction with 
recent stress in its association with antidepressant response, 
while rs7305115 of TPH2 and rs5569 of the noradrenaline trans-
porter gene SLC6A2 interacted with childhood trauma to inlu-
ence response to antidepressants (Xu et al., 2011, 2012).
Our previous studies focused on polymorphisms within 
exonic sequences of candidate genes involved primarily with 
serotonin and noradrenaline neurotransmission. In the cur-
rent work, we extended this study, again using a candidate gene 
approach, but including intronic and promoter polymorphisms. 
At the same time, we aimed to replicate some signiicant results 
reported in Caucasians in our Chinese Han sample. Again, inter-
actions between these polymorphisms and stressful life events 
were analyzed to obtain a better understanding of the role of 
both genetic and clinical factors in the response to antidepres-
sant treatment.
METHODS
Subjects
The subjects were Chinese Han in- and out-patients referred 
to 5 hospitals in Beijing, Nanjing, Changsha, Yangzhou, and 
Huai’an. All recruited patients were 18 to 60 years old, had a 
baseline HDRS-17 score of >17, presented depressive symptoms 
for at least 2 weeks, and met DSM-IV for nonpsychotic MDD. All 
subjects were newly diagnosed or recently relapsed patients 
drug-free for over 2 weeks. The patients were diagnosed by 2 
independent senior psychiatrists and conirmed by a third psy-
chiatrist who was blind to the previous evaluations. Exclusion 
criteria included documented history of diagnoses on Axis 1 
(including substance misuse, schizophrenia, schizoaffective 
disorder, bipolar disorder, generalized anxiety disorder, panic 
disorder, or obsessive compulsive disorder) of DSM-IV, person-
ality disorder, mental retardation, pregnancy, lactation, primary 
organic disease and other medical illnesses impairing psychiat-
ric evaluation, or a history of electroconvulsive therapy within 
the previous 6 months. Patients who suffered a manic episode 
during the 12 months after admission were excluded retrospec-
tively. All patients were interviewed and diagnosed by 2 inde-
pendent senior psychiatrists, and the diagnosis was conirmed 
by a third psychiatrist blinded to the previous evaluations. All 
subjects provided separate written informed consent for study 
participation, which was approved by each hospital ethical com-
mittee in accordance with the Declaration of Helsinki.
Antidepressant Treatment and Clinical Evaluation
MDD patients entering the study were given a single antide-
pressant drug (selective serotonin reuptake inhibitor [SSRI] or 
serotonin norepinephrine reuptake inhibitor [SNRI]) accord-
ing to local clinical practice for at least 6 weeks. Subjects were 
divided into subgroups by drug type and sex for further analy-
sis. A  meeting was held for investigators from the different 
sites before the onset of the study for assessment, training, 
 by guest on N
ovem
ber 8, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
Xu et al. | 3
and standardization of techniques. The assessing psychiatrists 
in different clinical centers achieved high inter-rater reliability, 
with an interclass  correlation of at least 0.9. We interviewed 
each patient every 2 weeks using a standardized protocol across 
centers, recording treatment duration, dosage, outcome, com-
pliance, and side effects. Severity of depressive symptoms was 
assessed using HDRS-17 by a trained senior psychiatrist who 
was blind to patients’ genotypes. Adjustment of antidepressant 
dose and usage of concomitant anxiolytics have been described 
previously (Xu et al., 2011). The primary outcome was “response,” 
deined by a reduction of ≥50% of the baseline HDRS-17 score 
after 6-week treatments (Xu et al., 2011). Patients who changed 
antidepressant drug or demonstrated nonadherence were retro-
spectively excluded from the study.
Two evaluation tools, the Childhood Trauma Questionnaire 
(28-item Short form, CTQ-SF) (Bemstein and Fink, 1998) and the 
Life Events Scale (LES) (Yang et al., 1999), were used to evaluate the 
occurrence of stressful life events that took place before the age 
of 16 years or during the previous year, respectively. Both of them 
are retrospective self-report questionnaires, and the details have 
been described previously (Xu et al., 2011). Control samples were 
not included in the present study; therefore, the control values of 
Fu et al. (2005) and Sun et al. (2008) were used to deine normal 
CTQ-SF and LES values, respectively. The total CTQ-SF and NLES 
scores were dichotomized for use in the gene-environment inter-
action analyses. A  total CTQ score ≥1 SD above the mean CTQ 
score (35.86 [8.25]) of control subjects (≥44.11) was designated “C 
high adversity”; <44.11 CTQ scores were designated “C low adver-
sity” (Fu et al., 2005). An NLES score ≥1 SD greater than the mean 
NLES (13.09 [25.16]) of control subjects (≥38.25) was designated 
“N high adversity”; <38.25 NLES scores were designated “N low 
adversity” (Sun et al., 2008; Enoch et al., 2010).
Gene Selection and Genotyping Method
The 20 candidate genes tested were selected based on evidence 
for the involvement of the monoaminergic system in antidepres-
sant mechanisms, and 64 SNPs in these genes were included on 
the basis of prior genetic or pharmacogenetic study. These were 
identiied using dbSNP (Map to Genome Build: 36.3) and HapMap 
(Public Release #24), were screened using the tagging SNP method 
(http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap24_
B36/), and then polymorphisms with reported minor allele fre-
quency (MAF) values of ≥5% were prioritized. Most of the SNPs 
were located in gene exon, intron, or promoter regions. Genomic 
DNA samples were genotyped using Illumina Golden Gate assays 
(Illumina Inc). SNPs that were genotyped successfully in <90% of 
all samples or had an experimental MAF of <5% were excluded. 
Likewise, participants in whom <90% of the selected markers were 
successfully determined were also excluded from further analysis.
Statistical Analysis
Differences in clinical variables between responder and nonre-
sponder groups were evaluated by Pearson’s χ2 test or ANOVA 
using SPSS version 13.0 (SPSS Inc). Haploview 4.0 was used to esti-
mate Hardy-Weinberg equilibrium, MAF, linkage disequilibrium 
(both D’ and r2), and the percentage of nonmissing each marker 
(%Gene). Genetic polymorphisms were correlated with therapeutic 
effects by comparing allele, genotype, and haplotype distributions 
between responders and nonresponders using UNPHASED-3.0.13 
(Dudbridge, 2003). One thousand random permutations were per-
formed with UNPHASED 3.0.13 software to correct P values for 
multiple testing in the allelic, genotypic, and haplotype association 
analyses. Furthermore, G×E interactions in association with thera-
peutic outcome were assessed by logistic regression analysis, using 
age, HDRS-17 baseline score, sex, and drug type as covariates. Logistic 
regression analyses were used to assess the effects of CTQ-SF, NLES, 
genotype, and interactions between genotype and CTQ-SF or NLES 
on the categorical outcome of antidepressant response. For the 
G×E analysis, only those SNPs that provided signiicant indings in 
the initial association were included (as each SNP thus had a valid 
a priori hypothesis). Each SNP was tested against 2 environmen-
tal conditions. Benjamini and Hochberg Discovery Rate Multiple 
Testing Correction was applied to the statistical signiicance of 
P < .05 (Benjamini and Hochberg., 1995).
RESULTS
A total of 281 patients met the study entry criteria and com-
pleted 6 weeks of antidepressant treatment. Among those, 205 
patients achieved response as deined by a 50% improvement in 
HAMD-17 score. Subgroups were SSRI (n = 164) vs SNRI (n = 117) 
and male (n = 116) vs female (n = 165). Of the 64 SNPs originally 
tested, 10 SNPs with MAF <5% or %Gene <95% were excluded, 
and 7 further SNPs were not in HW disequilibrium (P < .001), 
leaving 47 SNPs for inclusion in the analysis (Table 1).
The demographic and clinical characteristic of patients in 
the responder and nonresponder patient groups are shown in 
Table 2. There were no signiicant differences between the 2 sub-
groups in gender, age, years of education, or family history of 
mood disorder. However, the baseline HDRS-17 score was sig-
niicantly different between the 2 groups (F = 8.359, P = .004), as 
shown in Table 2.
An analysis of single locus effects revealed that 2 SNPs, 
rs11178998 and rs7963717, in TPH2 had a statistically signiicant 
association with antidepressant response, as shown in Table  3. 
There was genotypic association for each of these with antidepres-
sant response in the total group and in the SSRI subgroup, respec-
tively, which withstood permutation testing. There was allelic 
association of one further TPH2 SNP (rs2171363) with antidepres-
sant response in total group, withstanding permutation testing.
We examined the association of haplotypes derived from the 
SNPs in every gene with antidepressant response, limiting our 
analysis to haplotypes with a frequency ≥5%. Signiicant results 
were only found for TPH2. Table  4 shows the 2 haplotypes of 
TPH2 in relation to antidepressant response. The A-A haplo-
type was signiicantly associated with antidepressant response 
in the total group and in the SSRI subgroup, which withstood 
permutation testing. Compared with the A-G haplotype, the 
A-A haplotype was associated with increased likelihood of poor 
response in the total group (OR = 0.6959, 95% CI = 0.4259–1.136) 
and in the SSRI subgroup (OR = 0.5526, 95% CI = 0.2898–1.054). 
With the 3 SNPs of TPH2, the G-G-A haplotype was associated 
with antidepressant response in the total group (OR = 1.986, 95% 
CI = 1.018–3.872), but not withstanding permutation testing.
Among 281 subjects, 208 completed the CTQ-SF, of whom 
68 were categorized as high adversity based on their CTQ-SF 
score, and 219 completed the LES, of whom 78 were in the high 
adversity category based on their nLES score. In logistic regres-
sion analyses, there was no signiicant association between the 
categories derived from CTQ-SF or NLES and antidepressant 
outcome in the stepwise logistic regression model (results not 
shown). A further analysis searching for the interaction of these 
environmental measures with genotype in treatment response 
was then tested on the 3 SNPs with signiicant effects in the 
simple association analysis (rs11178998, rs7963717, rs2171363). 
A signiicant interaction between the TPH2 SNP rs2171363 and 
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CTQ-SF category was identiied in the effect on antidepres-
sant response, adjusting for age, gender, and HDRS-17 base-
line scores as covariates. The results are shown in Table  5 
(nonsigniicant results not shown). In the regression model 
with CTQ-SF and rs2171363, the interaction term (CTQ-SF by 
rs2171363 GG genotype) was associated with reduced response 
to antidepressants, with the CTQ low adversity and rs2171363 
AG/AA serving as reference (β = -2.432, SE = 1.060, OR = 0.088, 
95%CI: 0.011–0.702). A  further exploratory analysis search-
ing for gene-environment interactions in the remaining SNPs 
identiied no additional signiicant effects before any correc-
tion for multiple testing.
Discussion
In the initial investigation of associations of variants in mon-
oamine neurotransmitter system gene with antidepressant 
response in patients with MDD, we found that SNPs in TPH2 
were signiicantly associated with antidepressant response, and 
an interaction of one SNP in TPH2 and early life stress was also 
associated with antidepressant response.
There were genotypic associations for rs11178998, rs7963717, 
and rs2171363 in TPH2 with antidepressant response in the total 
group and, for the irst two, in the SSRI subgroup. rs11178998 
is located in the 5’ UTR and has previously been reported 
Table 1. Characteristics of Genotype Markers
Number Gene Name %geno HW P MAF Alleles
1 ADRA2A rs12246561 100 1 0.06 A:C
2 ADRA2A rs521674 100 .2271 0.297 T:A
3 ADRB1 rs17875446 99.6 .0792 0.146 G:T
4 COMT rs2020917 99.6 .024 0.243 G:A
5 COMT rs4680 98.2 1 0.277 G:A
6 COMT rs165774 100 .1613 0.171 G:A
7 COMT rs165599 99.6 .4011 0.479 A:G
8 HTR1A rs6295 100 .6515 0.254 C:G
9 HTR1B rs4140535 99.6 1 0.35 A:G
10 HTR1D rs674386 100 .6239 0.292 G:A
11 HTR2A rs7997012 99.6 1 0.234 G:A
12 HTR2A rs1923884 100 .1605 0.498 G:A
13 HTR2A rs2224721 99.6 .5167 0.323 C:A
14 HTR2A rs9316233 100 .2275 0.283 G:C
15 HTR2A rs2770296 98.6 .7639 0.253 A:G
16 HTR2A rs1928040 99.6 .804 0.266 A:G
17 HTR2A rs927544 100 .3008 0.286 A:G
18 HTR2A rs6313 99.6 .402 0.411 A:G
19 HTR2A rs6311 99.6 .6041 0.198 G:A
20 HTR2C rs3795182 99.6 0.157 A:G
21 HTR2C rs521018 100 0.173 A:C
22 HTR3A rs1062613 99.3 .9186 0.1 G:A
23 HTR3E rs10937162 98.9 .7334 0.317 G:C
24 HTR3E rs6443950 100 .7589 0.173 A:T
25 HTR4 rs1432919 100 .164 0.288 G:A
26 HTR4 rs2278392 100 .2402 0.29 G:A
27 HTR5A rs1881691 99.6 .3585 0.329 A:C
28 HTR5A rs3734966 99.3 .5743 0.113 A:G
29 HTR5A rs1800883 100 .0707 0.463 G:C
30 HTR7 rs1891311 100 .1058 0.183 A:G
31 MAOA rs979606 99.6 0.407 G:A
32 MAOA rs2064070 99.6 0.402 A:T
33 TH rs10770140 98.2 .0153 0.085 A:G
34 TH rs10840490 100 .0268 0.133 C:G
35 TH rs7115640 100 .7755 0.069 G:A
36 TPH1 rs7933505 100 .8807 0.496 G:A
37 TPH1 rs1799913 100 .8787 0.493 C:A
38 TPH1 rs1800532 100 1 0.489 C:A
39 TPH2 rs7963717 100 .4763 0.16 A:C
40 TPH2 rs4570625 100 1 0.44 A:C
41 TPH2 rs11178998 100 .396 0.164 A:G
42 TPH2 rs7954758 100 .2892 0.157 A:G
43 TPH2 rs1386494 100 1 0.084 G:A
44 TPH2 rs2171363 100 .269 0.459 A:G
45 TPH2 rs1487278 99.6 .2022 0.305 A:G
46 TPH2 rs1386483 99.6 .579 0.443 A:G
47 TPH2 rs1487279 99.6 .3369 0.454 T:A
Abbreviations: HW P, Hardy-Weinberg equilibrium P-value; %geno, percentage nonmissing; MAF, minor allele frequency.
Alleles means the major and minor alleles.
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to be associated with bipolar disorder (Cichon et  al., 2008). 
Furthermore, rs11178998 and rs7963717 were found to be in very 
high linkage disequilibrium in our study (Table  6), indicating 
that the inding may be due to the functional effect of a single 
SNP. There is also high linkage disequilibrium (D’ = 1, r2 > 0.99) 
between rs11178997 and rs11178998 reported in Chinese sub-
jects, these SNPs also showing strong linkage with rs4570625 in 
the 5’ region (Xu et al., 2013).
Results of a study investigating the effect of TPH2 promoter 
polymorphisms on transcriptional activity (Scheuch et al., 2007) 
Table 2. Demographic Characteristics of MDD Patients and Baseline HDRS-17 Scores between Responder and Nonresponder Groups
Demographic Characteristics Responder (n = 205) Nonresponder (n = 76) F/ χ2 P Value
Age (y) 38.99 ± 12.93 36.18 ± 13.36 2.556 0.111
Gender, male (female) 39.5% (60.5%) 46.1% (53.9%) 0.978 0.323
Antidepressant, SSRI (SNRI) 55.1% (44.9%) 65.8% (34.2%) 2.590 0.108
Duration of illness (mo) 48.42 ± 75.63 49.78 ± 68.83 0.019 0.892
Family history of mood disorder, yes (no) 16.1% (83.9%) 23.7% (76.3%) 2.148 0.143
First episode, yes (no) 51.7% (48.3%) 46.1% (53.9%) 0.709 0.400
Education, (y) 11.28 ± 3.71 12.20 ± 3.71 3.400 0.066
Baseline HDRS-17 score 28.18 ± 5.68 26.01 ± 5.32 8.359 0.004
Table 3. Genetic Association Analysis (Genotypic/Allelic) of SNPs vs Response Status in Total Group and the SSRI Subgroups
Gene/rs# Genotype/Allele RES NR RES-freq(%) NR-freq(%) P P** OR (95%CL)
Total group (n = 281)
TPH2/
rs11178998
AA 149 45 72.68 59.21 .03002 .03996 1.833 (1.056–3.18)
AA/AG* 56 31 27.32 40.79 .03002
TPH2/
rs7963717
AA 150 46 73.17 60.53 .04039 .03297 1.779 (1.022–3.096)
AC+CC* 55 30 26.83 39.47 .04039
TPH2/ 
rs2171363
A* 210 94 51.22 61.84
G 200 58 48.78 38.16 .02478 .01598 1.544 (1.055–2.258)
SSRI subgroup (n = 164)
TPH2/
rs11178998
AA 81 26 71.05 52.00 .01834 .02098 2.266 (1.14–4.503)
AA/AG* 33 24 28.95 48.00
TPH2/
rs7963717
AA 82 27 71.93 54.00 .02516 .02398 2.183 (1.095–4.352)
AC+CC* 32 23 28.07 46.00
Table 4. Estimated Haplotype Frequency of the TPH2 SNPs and the Results of Haplotype Analysis in Responders and Nonresponders
Gene/rs# Haplotype RES NR RES-freq(%) NR-freq(%) P P** OR (95%CL)
Total group (n = 281)
TPH2/
rs2171363, 
rs1487278
A-A 87.9 48 21.54 31.58 .01153 .03996 0.6959 (0.4259–1.136)
A-G* 121.1 46 29.68 30.26
G-A 195.1 58 47.82 38.16
TPH2/
rs1386494,
rs2171363,  
rs1487278
A-A-A 28.85 17 70.70 11.18
G-A-A 58.71 31 14.39 20.39
G-A-G* 120.3 46 29.48 30.26
G-G-A 195.4 58 47.90 38.16 .0364 .1239 1.986 (1.018–3.872)
SSRI subgroup (n = 164)
TPH2/
rs2171363, 
rs1487278
A-A 44.53 32 19.53 32.00 .01203 .02697 0.5526 (0.2898–1.054)
A-G* 65.47 26 28.72 26.00
G-A 115.5 42 50.65 42.00
Table 5. Results of the Interactions between rs2171363 and CTQ-SF on Antidepressant Response Adjusting for Age, Gender, and Baseline HDRS-
17 Score
β SE P Odds Ratio 95% CI
Baseline HDRS-17 score 0.112 0.033 0.001 1.118 1.049–1.192
Gender 0.222 0.336 0.509 1.248 0.646–2.411
Age -0.005 0.013 0.713 0.995 0.969–1.021
CTQ-SF 0.205 0.376 0.585 1.227 0.588–2.564
rs2171363 2.019 0.776 0.009 7.529 1.646–34.434
rs2171363 by CTQ-SF interaction -2.432 1.060 0.022 0.088 0.011–0.702
Abbreviation: CTQ-SF, Childhood Trauma Questionnaire.
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indicated that the A-allele of rs11178997 signiicantly reduces 
TPH2 transcriptional activity via an effect on transcription fac-
tor binding, while rs4570625 was found to have no inluence on 
transcription. However, a subsequent study (Chen et  al., 2008) 
found both of these regulatory sequence SNPs inluenced, in a 
synergistic manner, gene expression, while rs11178998 also had 
a strong effect on transcriptional activity independent of the 
other 2 SNPs. These data suggest that the functional effects of 
rs11178997 and/or rs11178998 may well contribute to the associ-
ation of rs11178998 and rs7963717 with antidepressant response
Several other groups have shown association of rs4570625 
with psychiatric disorders, including schizophrenia (Xu et  al., 
2014) and epileptic psychosis (Bragatti et al., 2014) and, interest-
ingly in this context, an interaction of the SNP with maternal 
depression in infant response to fearful expression (Forssman 
et al., 2014). However, we ind that this SNP is not signiicantly 
related to outcome measures in our study. This is likely due to 
the fact that while this SNP is in linkage disequilibrium with the 
functional rs11178997 and the closely linked rs11178998 that we 
measured, the MAFs are very different, resulting in r2 = 0.15.
The third TPH2 SNP, rs2171363, signiicantly associated with 
antidepressant response in the total group, but not with the SSRI 
subgroup, was also associated with antidepressant response in 
another study of Chinese patients (Tsai et al., 2009). This effect 
may be additional to that of the 2 promoter SNPs; rs2171363 is 
found in a large intronic sequence approximately 30 kb removed 
from the 5’ regulatory sequence and this SNP is not in strong 
linkage disequilibrium with the previous 2 (Table 6).
This rs2171363, but not the 2 other SNPs signiicantly associ-
ated with antidepressant response, shows a signiicant interac-
tion with early life stress in this effect. This inding, in which 
the GG genotype and high childhood adversity were related to 
poor treatment response, is notable in light of our initial ind-
ing of such a gene-environment interaction with antidepressant 
response with this sample (Xu et al., 2012). The current indings 
appear to be a replication of the original effect; rs2171363 and 
the previously reported rs7305115 are in close linkage disequi-
librium and are thus likely to show any association together. 
The mechanism underlying the association with antidepressant 
response is unclear; rs2171363 is intronic, while rs7305115 is a 
synonymous exonic SNP. However, there is a report that these 
are 2 of 5 SNPs within a closely linked haplotype block, each cor-
relating with TPH2 mRNA expression (Lim et al., 2007).
Furthermore, the mechanism underlying the interactions 
between genetic variation in TPH2 and early stressors is also 
far from clear. One speculative explanation for the gene-envi-
ronment interaction in our study might be that early life stress 
results in epigenetic changes such as DNA methylation and that 
this may interact with proximal polymorphisms, perhaps by 
inluencing transcription factor binding, to modify gene expres-
sion. There is certainly evidence for this in terms of the relation-
ship between early life stress and depression (Dalton et al., 2014) 
and has also been indicated as a factor inluencing treatment 
response of some symptoms in schizophrenia (Tang et al., 2014).
The 2 TPH2 SNPs that showed no signiicant effects in our 
genotype and allele analysis, rs1487278 and rs1386494, have 
previously been reported to be associated with antidepres-
sant response and treatment resistant depression, respec-
tively (Tzvetkov et al., 2008; Anttila et al., 2009; Tsai et al., 2009). 
Haplotype analysis undertaken according to the haplotype 
blocks deined by the SNPs in this study has not shown any 
effect stronger than individual signiicant component SNPs.
The results of this study would beneit from being repli-
cated in a further sample, and a second collection is currently T
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underway to address this. It would also be valuable to know 
whether the indings could be extrapolated to other ethnicities. 
As with all such studies, a larger sample would be more inform-
ative; this could enable the investigation of possible differential 
effects of sex, individual drugs, and further social or epidemio-
logical variables as well as permitting better study of gene inter-
actions with these factors and between genes. Furthermore, 
the differences in signiicant association between the whole 
sample and the SSRI subgroup may relect the limited sample 
size rather than any subgroup speciicity. We recognize that the 
retrospective and subjective determination of prior stressors is 
imprecise, and treating these as dichotomized categorical vari-
ables limits the analytical power. It is important to recognize 
that in this small study we have not investigated all the genetic 
factors that might contribute to functional effects on serotonin 
or noradrenaline neurotransmission, nor have we comprehen-
sively assessed the genetic variability within the chosen candi-
date genes, having selected speciic SNPs on the basis of prior 
study and likely or known functionality. Nevertheless, our ind-
ings provide an interesting and potentially valuable insight into 
possible genetic factors and gene-environment interactions that 
inluence outcome in the treatment of depression.
In conclusion, we ind 3 associations of genetic variabil-
ity within TPH2 with response to treatment in our sample of 
Chinese subjects with depression. Only one of these demon-
strates an interaction with early life stress, a inding which 
suggests a sequence-speciic epigenetic consequence of this 
environmental factor that may be modiied by the identiied 
polymorphism, or one in close linkage. Further study needs to 
identify the effects of these genetic variants on gene expres-
sion and on the possible mechanisms relating early life stress to 
response to treatment with antidepressant drugs.
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